Bl-M14D1
Metastatic Neuroendocrine Prostate Cancer
SystImmune Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
32 Active assets in the Metastatic Neuroendocrine Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Phanes Therapeutics | Phase 2 | BB |
Tarlatamab Inkeun Park | Phase 2 | B |
Oxodotreotide Novartis Pharmaceuticals | Phase 2 | B |
Alisertib Weill Medical College of Cornell University | Phase 2 | B |
Ipilimumab Andrew J. Armstrong, MD | Phase 2 | CCC |
View all 35 →
Same molecule, other indications
Bl-M14D1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →